More science – Bursting with ideas


Idorsia is a high-potential biopharmaceutical company, with an experienced team of over 1,200 highly qualified professionals, a full R&D pipeline, state-of-the-art facilities, and a strong balance sheet – the ideal constellation for bringing successful medicines to the market.

We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.

Idorsia is specialized in the discovery and development of small molecules, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified and balanced development pipeline, covering multiple therapeutic areas. Our clinical pipeline comprises 11 assets, 6 of which are in late-stage development, and we expect to see two product launches in two of the largest pharmaceutical markets in the second quarter of 2022. With this in mind, we have built a commercial organization to bring our products to patients.

Idorsia is a start-up like no other!

Our Strategy

Our Strategy

Find out more about how Idorsia intends to deliver on its ambitious goals.

Idorsia pipeline

Idorsia pipeline

See an overview of Idorsia's clinical development pipeline.

History

History

Learn more about how Idorsia came to life.